RARE

Ultragenyx PharmaceuticalB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$25.70

Analysis reference price unavailable

Analysis 2026-09-04 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$17.00

Analysis reference price unavailable

Analysis 2026-09-04 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$9.00

Analysis reference price unavailable

Analysis 2026-09-04 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-04

AI commentary

News tone is sharply negative after the GTX-102 failure, with high headline attention and an approximately 45% reported premarket decline; see [Ultragenyx shares fall after Phase 3 Aspire study misses primary endpoint](https://finance.yahoo.com/healthcare/articles/ultragenyx-shares-fall-phase-3-110050243.html). Social coverage, options data, short interest, employee sentiment, and post-print analyst revisions are unavailable or unvalidated, so the setup remains a cautious monitoring view.

RankAlpha Sentiment Codex - 2026-09-04

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-02catalystAspire Phase 3 failure resets pipeline valueHigh impact

Ultragenyx reported that GTX-102 missed both the Bayley-4 cognitive primary endpoint and MDRI key secondary endpoint; program disposition is under review and significant expense reductions are planned. Secondary coverage reported an approximately 45% premarket decline, so much of the initial shock appears priced in. [#SEC-8K-2026-09-02]

2026-12-03eventUnresolved gene-therapy regulatory read-throughHigh impact

The August earnings exhibit identified two second-half 2026 PDUFA catalysts, including DTX-401's August 23 action date, but the packet does not confirm the decision status or provide UX-111's exact date. This remains a monitoring catalyst rather than a high-conviction upside trigger. [#SEC-8K-2026-08-04]

2027-09-04catalystCommercial base and profitability executionHigh impact

Q2 revenue was $214 million, described as the company's highest quarterly revenue, with 2026 revenue guidance reaffirmed at $730-$760 million excluding potential new launches and profitability still targeted for 2027. Execution and cost reductions could provide support, but the failed trial raises uncertainty around the broader portfolio. [#SEC-8K-2026-08-04] [#SEC-8K-2026-09-02]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-04 • Updated nightlySource: Internal modelMethodology